S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

Orchard Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
29.7% Upside
$21.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Orchard Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.25) to ($4.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.75 out of 5 stars

Medical Sector

827th out of 957 stocks

Biotechnology Industry

15th out of 24 stocks


ORTX stock logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..


ORTX Stock News Headlines

Memory Care Communities Near Orchard Grass Hills, KY
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Senior Living Communities Near Old Orchard Beach, ME
Senior Living Communities Near Orchard Lake Village, MI
Assisted Living Communities Near Orchard Grass Hills, KY
Assisted Living Communities Near Orchard Lake Village, MI
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Assisted Living Communities Near Old Orchard, PA
Independent Living Communities Near Old Orchard, PA
Teen arrested for arsons in Port Orchard
ORTX Mar 2024 15.000 call
Gettysburg's Peach Orchard holds juicy stories
See More Headlines
Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2023
Today
3/01/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$34.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+29.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-150,660,000.00
Net Margins
-333.90%
Pretax Margin
-334.54%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Book Value
$7.74 per share

Miscellaneous

Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Hubert Baburaj Gaspar M.D. (Age 61)
    Ph.D., CEO, Member of Scientific Advisory Board & Executive Director
    Comp: $901.42k
  • Mr. Frank Edward Thomas (Age 55)
    President & COO
    Comp: $763.95k
  • Dr. Nicoletta Loggia Ph.D.
    R.Ph., Chief Technical Officer
  • Dr. Fulvio Mavilio Ph.D.
    Chief Scientific Officer
  • Ms. Renee T. Leck
    Head of Investor Relations
  • Benjamin Navon
    Director of Corporate Communications
  • Mr. John Cerio
    Chief Human Resource Officer
  • Mr. Robin Kenselaar
    Senior VP & GM of EMEA Commercial Operations
  • Mr. Braden Parker
    Chief Commercial Officer
  • Dr. Leslie Meltzer Ph.D.
    Chief Medical Officer














ORTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchard Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View ORTX analyst ratings
or view top-rated stocks.

What is Orchard Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 1 year target prices for Orchard Therapeutics' stock. Their ORTX share price targets range from $15.00 to $34.00. On average, they expect the company's stock price to reach $21.67 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts price targets for ORTX
or view top-rated stocks among Wall Street analysts.

When is Orchard Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ORTX earnings forecast
.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($1.61) by $1.49. The company earned $1.24 million during the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 74.94% and a negative net margin of 333.90%.

When did Orchard Therapeutics' stock split?

Shares of Orchard Therapeutics reverse split on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Blue Owl Capital Holdings LP (7.03%), Beryl Capital Management LLC (6.86%), Gabelli Funds LLC (0.99%), GABELLI & Co INVESTMENT ADVISERS INC. (0.85%), Goldman Sachs Group Inc. (0.60%) and Prelude Capital Management LLC (0.51%). Insiders that own company stock include Bobby Gaspar and Frank E Thomas.
View institutional ownership trends
.

This page (NASDAQ:ORTX) was last updated on 3/1/2024 by MarketBeat.com Staff